Philippe Cinquin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Philippe Cinquin has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Cordélia Salomez-Ihl
Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Grenoble, France
5 shared publications - François Boucher
Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Grenoble, France
5 shared publications - Jean-Pierre Alcaraz
Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC
5 shared publications - Thomas Soranzo
Pelican Health , 38700 La Tronche
3 shared publications - Abdelkader Zebda
TIMC-IMAG/CNRS/INSERM, UMR 5525, Université Grenoble Alpes, Grenoble 38000, France
2 shared publications - Aleksandra Milovančev
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Respiratory-physiology modeling of therapeutic hydrogen inhalation: defining the fraction of inspired hydrogen (FiH2) and flow-rate requirements
Molecular hydrogen (H2 gas) has emerged as a promising therapeutic agent with reported benefits across oxidative stress, inflammation, cardiovascular, and
- 28 April 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessRespiratory-physiology modeling of therapeutic hydrogen inhalation: defining the fraction of inspired hydrogen (FiH2) and flow-rate requirements
Molecular hydrogen (H2 gas) has emerged as a promising therapeutic agent with reported benefits across oxidative stress, inflammation, cardiovascular, and
- Open Access
Profiling the human luminal small intestinal microbiome using a novel ingestible medical device
The invasive nature of sample collection for studying the small intestinal (SI) microbiome often results in its poor characterization. This study evaluated a novel ingestible medical device (MD) for SI luminal sample collection. A monocentric interventional trial ( NCT05477069 ) was conducted on 15 healthy subjects. Metagenomics, metabolomics and culturomics assessed the MD’s effectiveness in characterizing the healthy SI microbiome and identifying potential biomarkers. The SI microbiota differed significantly from the fecal microbiota, displaying high inter-individual variability, lower species richness, and reduced alpha diversity. A combined untargeted and semi-targeted LC-MS/MS metabolomics approach identified a distinct SI metabolic footprint, with bile acids and amino acids being the most abundant classes of metabolites. Host and host/microbe-derived bile acids were particularly abundant in SI samples. The application of a fast culturomics approach to two SI samples enabled species-level characterization, resulting in the identification of 90 bacterial species, including five potential novel species. The present study demonstrates the efficacy of our novel sampling MD in enabling comprehensive SI microbiome analysis through an integrative multi-omics approach, allowing the identification of distinct microbiome signatures between SI and fecal samples.
Open AccessProfiling the human luminal small intestinal microbiome using a novel ingestible medical device
The invasive nature of sample collection for studying the small intestinal (SI) microbiome often results in its poor characterization. This study evaluated a novel ingestible medical device (MD) for SI luminal sample collection. A monocentric interventional trial ( NCT05477069 ) was conducted on 15 healthy subjects. Metagenomics, metabolomics and culturomics assessed the MD’s effectiveness in characterizing the healthy SI microbiome and identifying potential biomarkers. The SI microbiota differed significantly from the fecal microbiota, displaying high inter-individual variability, lower species richness, and reduced alpha diversity. A combined untargeted and semi-targeted LC-MS/MS metabolomics approach identified a distinct SI metabolic footprint, with bile acids and amino acids being the most abundant classes of metabolites. Host and host/microbe-derived bile acids were particularly abundant in SI samples. The application of a fast culturomics approach to two SI samples enabled species-level characterization, resulting in the identification of 90 bacterial species, including five potential novel species. The present study demonstrates the efficacy of our novel sampling MD in enabling comprehensive SI microbiome analysis through an integrative multi-omics approach, allowing the identification of distinct microbiome signatures between SI and fecal samples.
- Open Access
Indoor air quality at a French university: a participatory CO2 measurement campaign highlights the wide gap between reality and the law
Poor indoor air quality has been demonstrated to increase the risk of transmitting infectious agents and to expose individuals to the phenomenon of sick building syndrome. In light of these findings, most countries have established specific guidelines regarding indoor air quality in university rooms. In France, for instance, the maximum permissible concentration of carbon dioxide (CO 2 ) in university rooms without mechanical ventilation is set at 1,300 parts per million (ppm), and the minimum volume per occupant is 15 m 3 . For rooms with mechanical ventilation, the minimum clean air flow rate is 25 m 3 /h/occupant. The primary objective of this study was to design and demonstrate the feasibility of a simple, cost-effective method for comparing the reality of indoor air quality in all university rooms with legal requirements. The secondary objectives of the present study were to demonstrate the efficacy of the proposed method in identifying and reporting problematic situations, and in issuing practical recommendations. Mobile CO 2 sensors (Aranet4) were provided to volunteer lecturers to measure the CO 2 concentration during and after classes. The number of occupants and the condition of openings were also recorded. These data were supplemented by measurements from 117 fixed Carbon Nexelec sensors. The data were then fitted to a model, which enabled the characterization of air quality and the estimation of the gauge reduction required to comply with the law. None of the 14 rooms without mechanical ventilation complied with the legal minimum of 15 m 3 /occupant. 75% of the third quartiles of CO 2 concentrations during classes exceeded 2692 ppm. In rooms with mechanical ventilation, median clean air flow was 15 m 3 /h/occupant at 100% occupancy (9 m 3 /h/occupant for the first quartile). In 32 out of 41 rooms with mechanical ventilation (78%), the clean air flow was estimated to be below the legal minimum of 25 m 3 /h/occupant at 100% occupancy. Concentrations in excess of 5,000 ppm were observed in 23 of the 101 rooms equipped with fixed sensors. The proposed method has demonstrated its feasibility in real-life conditions. For the purpose of evaluating the air quality of all rooms affiliated with universities, it is recommended that this method be used in a systematic manner. The findings of this study indicate that a significant proportion of the examined rooms may not be in accordance with the relevant legislation, thereby jeopardizing the health of the occupants. In order to comply with the law, the method proposed here to estimate gauge reduction should be applied.
Open AccessIndoor air quality at a French university: a participatory CO2 measurement campaign highlights the wide gap between reality and the law
Poor indoor air quality has been demonstrated to increase the risk of transmitting infectious agents and to expose individuals to the phenomenon of sick building syndrome. In light of these findings, most countries have established specific guidelines regarding indoor air quality in university rooms. In France, for instance, the maximum permissible concentration of carbon dioxide (CO 2 ) in university rooms without mechanical ventilation is set at 1,300 parts per million (ppm), and the minimum volume per occupant is 15 m 3 . For rooms with mechanical ventilation, the minimum clean air flow rate is 25 m 3 /h/occupant. The primary objective of this study was to design and demonstrate the feasibility of a simple, cost-effective method for comparing the reality of indoor air quality in all university rooms with legal requirements. The secondary objectives of the present study were to demonstrate the efficacy of the proposed method in identifying and reporting problematic situations, and in issuing practical recommendations. Mobile CO 2 sensors (Aranet4) were provided to volunteer lecturers to measure the CO 2 concentration during and after classes. The number of occupants and the condition of openings were also recorded. These data were supplemented by measurements from 117 fixed Carbon Nexelec sensors. The data were then fitted to a model, which enabled the characterization of air quality and the estimation of the gauge reduction required to comply with the law. None of the 14 rooms without mechanical ventilation complied with the legal minimum of 15 m 3 /occupant. 75% of the third quartiles of CO 2 concentrations during classes exceeded 2692 ppm. In rooms with mechanical ventilation, median clean air flow was 15 m 3 /h/occupant at 100% occupancy (9 m 3 /h/occupant for the first quartile). In 32 out of 41 rooms with mechanical ventilation (78%), the clean air flow was estimated to be below the legal minimum of 25 m 3 /h/occupant at 100% occupancy. Concentrations in excess of 5,000 ppm were observed in 23 of the 101 rooms equipped with fixed sensors. The proposed method has demonstrated its feasibility in real-life conditions. For the purpose of evaluating the air quality of all rooms affiliated with universities, it is recommended that this method be used in a systematic manner. The findings of this study indicate that a significant proportion of the examined rooms may not be in accordance with the relevant legislation, thereby jeopardizing the health of the occupants. In order to comply with the law, the method proposed here to estimate gauge reduction should be applied.
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in ISME Communications
- Vol. 5 (1)
Exploring the human small intestinal luminal microbiome via a newly developed ingestible sampling device
Because accessing the small intestine is technically challenging, studies of the small intestinal microbiome are predominantly conducted in patients rather than in healthy individuals. Invasive clinical procedures, such as endoscopy or surgery, usually performed for therapeutic purposes, are typically required for sample collection. Although stomas offer a less invasive means for repeated sampling, their use remains restricted to patient populations. As a result, the small intestinal microbiome of healthy individuals remains largely understudied. This study evaluated a novel ingestible medical device for collecting luminal samples from the small intestine. A monocentric interventional trial (NCT05477069) was conducted on 15 healthy subjects. Metagenomics, metabolomics, and culturomics were used to assess the effectiveness of the medical device in characterizing the healthy small intestinal microbiome and identifying potential biomarkers. The small intestinal microbiota differed significantly from the fecal microbiota, displaying high inter-individual variability, lower species richness and reduced alpha diversity. A combined untargeted and semi-targeted LC–MS/MS metabolomics approach identified a distinct small intestinal metabolic footprint, with bile acids and amino acids being the most abundant metabolite classes. Host- and host/microbe-derived bile acids were particularly abundant in small intestinal samples. Using a fast culturomics approach on two small intestinal samples, we achieved species-level characterization and identified 90 bacterial species, including five potentially novel ones. This study demonstrates the efficacy of our novel sampling device in enabling comprehensive small intestinal microbiome analysis through an integrative, multi-omics approach. This approach allows distinct microbiome signatures to be identified between small intestinal and fecal samples.
- 17 January 2025
- Published by Oxford University Press (OUP) in ISME Communications
- Vol. 5 (1)
Open AccessExploring the human small intestinal luminal microbiome via a newly developed ingestible sampling device
Because accessing the small intestine is technically challenging, studies of the small intestinal microbiome are predominantly conducted in patients rather than in healthy individuals. Invasive clinical procedures, such as endoscopy or surgery, usually performed for therapeutic purposes, are typically required for sample collection. Although stomas offer a less invasive means for repeated sampling, their use remains restricted to patient populations. As a result, the small intestinal microbiome of healthy individuals remains largely understudied. This study evaluated a novel ingestible medical device for collecting luminal samples from the small intestine. A monocentric interventional trial (NCT05477069) was conducted on 15 healthy subjects. Metagenomics, metabolomics, and culturomics were used to assess the effectiveness of the medical device in characterizing the healthy small intestinal microbiome and identifying potential biomarkers. The small intestinal microbiota differed significantly from the fecal microbiota, displaying high inter-individual variability, lower species richness and reduced alpha diversity. A combined untargeted and semi-targeted LC–MS/MS metabolomics approach identified a distinct small intestinal metabolic footprint, with bile acids and amino acids being the most abundant metabolite classes. Host- and host/microbe-derived bile acids were particularly abundant in small intestinal samples. Using a fast culturomics approach on two small intestinal samples, we achieved species-level characterization and identified 90 bacterial species, including five potentially novel ones. This study demonstrates the efficacy of our novel sampling device in enabling comprehensive small intestinal microbiome analysis through an integrative, multi-omics approach. This approach allows distinct microbiome signatures to be identified between small intestinal and fecal samples.
- Open Access
- 7 August 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (8) , e0057324
H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-dose design, seeks to assess the safety and tolerability of the procedure in individuals with confirmed SARS-CoV-2 infection. Employing a 3 + 3 design, the study includes three exposure durations (target durations): 1 day (D1), 3 days (D2), and 6 days (D3). We concluded that the maximum tolerated duration is at least 3 days. Every patient showed clinical improvement and excellent tolerance to H2 therapy. To the best of our knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H2 (3.6%) and N2 (96.4%) in hospitalized COVID-19 patients. The original device and method employed ensure the absence of explosion risk. The encouraging outcomes observed in the 12 patients included in the study justify further exploration through larger, controlled clinical trials. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04633980 .
- 7 August 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (8) , e0057324
Open AccessH 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-dose design, seeks to assess the safety and tolerability of the procedure in individuals with confirmed SARS-CoV-2 infection. Employing a 3 + 3 design, the study includes three exposure durations (target durations): 1 day (D1), 3 days (D2), and 6 days (D3). We concluded that the maximum tolerated duration is at least 3 days. Every patient showed clinical improvement and excellent tolerance to H2 therapy. To the best of our knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H2 (3.6%) and N2 (96.4%) in hospitalized COVID-19 patients. The original device and method employed ensure the absence of explosion risk. The encouraging outcomes observed in the 12 patients included in the study justify further exploration through larger, controlled clinical trials. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04633980 .
- Open Access
- 24 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4308
Molecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial
Background. Due to its antioxidant, anti-inflammatory, anti-apoptosis, and anti-fatigue properties, molecular hydrogen (H2) is potentially a novel therapeutic nutrient for patients with coronavirus acute disease 2019 (COVID-19). We determined the efficacy and safety profile of hydrogen-rich water (HRW) to reduce the risk of COVID-19 progression. Methods: We also conducted a phase 3, triple-blind, randomised, placebo-controlled trial to evaluate treatment with HRW initiated within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19. Participants were randomised to receive HRW or placebo twice daily for 21 days. The incidence of clinical worsening and adverse events were the primary endpoints. Results: A total of 675 participants were followed up to day 30. HRW was not superior to placebo in preventing clinical worsening at day 14: in H2 group, 46.1% in the H2 group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90–1.31]. One death was reported at day 30 in the H2 group and two in the placebo group at day 30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants, respectively. Conclusions: HRW taken twice daily from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening.
- 24 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4308
Open AccessMolecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial
Background. Due to its antioxidant, anti-inflammatory, anti-apoptosis, and anti-fatigue properties, molecular hydrogen (H2) is potentially a novel therapeutic nutrient for patients with coronavirus acute disease 2019 (COVID-19). We determined the efficacy and safety profile of hydrogen-rich water (HRW) to reduce the risk of COVID-19 progression. Methods: We also conducted a phase 3, triple-blind, randomised, placebo-controlled trial to evaluate treatment with HRW initiated within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19. Participants were randomised to receive HRW or placebo twice daily for 21 days. The incidence of clinical worsening and adverse events were the primary endpoints. Results: A total of 675 participants were followed up to day 30. HRW was not superior to placebo in preventing clinical worsening at day 14: in H2 group, 46.1% in the H2 group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90–1.31]. One death was reported at day 30 in the H2 group and two in the placebo group at day 30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants, respectively. Conclusions: HRW taken twice daily from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening.
- Open Access
Molecular hydrogen for outpatients with Covid-19 (Hydro-Covid): a phase 3, randomised, triple-blinded, adaptive, placebo-controlled, multicentre trial
Background: Due to its antioxidative, anti-inflammatory, anti-apoptosis, and antifatigue properties, molecular hydrogen (H 2 ) is potentially a novel therapeutic gas for acute coronavirus disease 2019 (COVID-19) patients. Aim: To determine the efficacy and safety profile of hydrogen rich water (HRW) to reduce the risk of progression of COVID-19. Design and settings: We conducted a phase 3, triple-blind, randomized, placebo-controlled trial to evaluate treatment with HRW started within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19 and at least one risk factor for severe COVID-19 illness. Method: Participants were randomly assigned to receive HRW or placebo twice daily for 21 days. The composite primary endpoint was the incidence of clinical worsening (dyspnea, fatigue) associated with a need for oxygen therapy, hospitalization or death at day-14; the incidence of adverse events was the primary safety end point. Results: A total of 675 participants were followed up until day-30. 337 in the HRW group and 338 in the placebo group. Baseline characteristics were similar in the two groups. HRW was not superior to placebo in preventing clinical worsening at day-14: in H 2 group, 46.1% met a clinical deterioration, 43.5% in the placebo group, Hazard Ratio 1.09, 90% confidence interval [0.90-1.31]. One death was reported in the H 2 group and 2 in the placebo group at day-30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants respectively. Conclusion: Twice-daily ingestion of HRW from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening. How this fits in: Only a few molecules specially developed against SARS-CoV-2 can limit impact of COVID-19 (vaccines, monoclonal antibodies or antiviral drugs) Using their multiple properties, H2 may play a key role in preventing the severe and post-acute forms of COVID-19 Taking twice daily Hydrogen Rich Water (HRW) was not efficacious to prevent severe COVID-19 in at risk COVID-19 patients. HRW confirmed a very safe profil
Open AccessMolecular hydrogen for outpatients with Covid-19 (Hydro-Covid): a phase 3, randomised, triple-blinded, adaptive, placebo-controlled, multicentre trial
Background: Due to its antioxidative, anti-inflammatory, anti-apoptosis, and antifatigue properties, molecular hydrogen (H 2 ) is potentially a novel therapeutic gas for acute coronavirus disease 2019 (COVID-19) patients. Aim: To determine the efficacy and safety profile of hydrogen rich water (HRW) to reduce the risk of progression of COVID-19. Design and settings: We conducted a phase 3, triple-blind, randomized, placebo-controlled trial to evaluate treatment with HRW started within 5 days after the onset of signs or symptoms in primary care patients with mild-to-moderate, laboratory-confirmed COVID-19 and at least one risk factor for severe COVID-19 illness. Method: Participants were randomly assigned to receive HRW or placebo twice daily for 21 days. The composite primary endpoint was the incidence of clinical worsening (dyspnea, fatigue) associated with a need for oxygen therapy, hospitalization or death at day-14; the incidence of adverse events was the primary safety end point. Results: A total of 675 participants were followed up until day-30. 337 in the HRW group and 338 in the placebo group. Baseline characteristics were similar in the two groups. HRW was not superior to placebo in preventing clinical worsening at day-14: in H 2 group, 46.1% met a clinical deterioration, 43.5% in the placebo group, Hazard Ratio 1.09, 90% confidence interval [0.90-1.31]. One death was reported in the H 2 group and 2 in the placebo group at day-30. Adverse events were reported in 91 (27%) and 89 (26.2%) participants respectively. Conclusion: Twice-daily ingestion of HRW from the onset of COVID-19 symptoms for 21 days did not reduce clinical worsening. How this fits in: Only a few molecules specially developed against SARS-CoV-2 can limit impact of COVID-19 (vaccines, monoclonal antibodies or antiviral drugs) Using their multiple properties, H2 may play a key role in preventing the severe and post-acute forms of COVID-19 Taking twice daily Hydrogen Rich Water (HRW) was not efficacious to prevent severe COVID-19 in at risk COVID-19 patients. HRW confirmed a very safe profil
- Open Access
Electrochemical Biosensing of Glucose Based on the Enzymatic Reduction of Glucose
In this work, the enzyme aldehyde reductase, also known as aldose reductase, was synthesized and cloned from a human gene. Spectrophotometric measurements show that in presence of the nicotinamide adenine dinucleotide phosphate cofactor (NADPH), the aldehyde reductase catalyzed the reduction of glucose to sorbitol. Electrochemical measurements performed on an electrodeposited poly(methylene green)-modified gold electrode showed that in the presence of the enzyme aldehyde reductase, the electrocatalytic oxidation current of NADPH decreased drastically after the addition of glucose. These results demonstrate that aldehyde reductase is an enzyme that allows the construction of an efficient electrochemical glucose biosensor based on glucose reduction.
Open AccessElectrochemical Biosensing of Glucose Based on the Enzymatic Reduction of Glucose
In this work, the enzyme aldehyde reductase, also known as aldose reductase, was synthesized and cloned from a human gene. Spectrophotometric measurements show that in presence of the nicotinamide adenine dinucleotide phosphate cofactor (NADPH), the aldehyde reductase catalyzed the reduction of glucose to sorbitol. Electrochemical measurements performed on an electrodeposited poly(methylene green)-modified gold electrode showed that in the presence of the enzyme aldehyde reductase, the electrocatalytic oxidation current of NADPH decreased drastically after the addition of glucose. These results demonstrate that aldehyde reductase is an enzyme that allows the construction of an efficient electrochemical glucose biosensor based on glucose reduction.
- Open Access
- 23 April 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (8) , 2923
Challenges for the Implantation of Symbiotic Nanostructured Medical Devices
We discuss the perspectives of designing implantable medical devices that have the criterion of being symbiotic. Our starting point was whether the implanted device is intended to have any two-way (“duplex”) communication of energy or materials with the body. Such duplex communication extends the existing concepts of a biomaterial and biocompatibility to include the notion that it is important to consider the intended functional use of the implanted medical device. This demands a biomimetic approach to design functional symbiotic implantable medical devices that can be more efficient in mimicking what is happening at the molecular and cellular levels to create stable interfaces that allow for the unfettered exchanges of molecules between an implanted device and a body. Such a duplex level of communication is considered to be a necessary characteristic of symbiotic implanted medical devices that are designed to function for long periods of time inside the body to restore and assist the function of the body. We illustrate these perspectives with experience gained from implanting functional enzymatic biofuel cells.
- 23 April 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (8) , 2923
Open AccessChallenges for the Implantation of Symbiotic Nanostructured Medical Devices
We discuss the perspectives of designing implantable medical devices that have the criterion of being symbiotic. Our starting point was whether the implanted device is intended to have any two-way (“duplex”) communication of energy or materials with the body. Such duplex communication extends the existing concepts of a biomaterial and biocompatibility to include the notion that it is important to consider the intended functional use of the implanted medical device. This demands a biomimetic approach to design functional symbiotic implantable medical devices that can be more efficient in mimicking what is happening at the molecular and cellular levels to create stable interfaces that allow for the unfettered exchanges of molecules between an implanted device and a body. Such a duplex level of communication is considered to be a necessary characteristic of symbiotic implanted medical devices that are designed to function for long periods of time inside the body to restore and assist the function of the body. We illustrate these perspectives with experience gained from implanting functional enzymatic biofuel cells.